- Home
- GCTS vs ATYR Comparison
GCTS vs ATYR Comparison
Compare GCTS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCTS | ATYR |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 79.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GCTS | ATYR |
|---|---|---|
| Price | $1.41 | $0.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.50 | ★ $8.75 |
| AVG Volume (30 Days) | 119.6K | ★ 2.6M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,893,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,205.88 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $0.64 |
| 52 Week High | $2.76 | $7.29 |
Technical Indicators
Market Signals| Indicator | GCTS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 39.24 |
| Support Level | $1.40 | $0.70 |
| Resistance Level | $1.49 | $0.83 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 61.90 | 20.19 |
Price Performance
Historical ComparisonAbout GCTS GCT Semiconductor Holding Inc.
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.